肿瘤外科医生不懂肿瘤是什么：他们切除肿瘤并"清扫"淋巴结，他认为这是错误的。
原始表述
عليا بقى بتوع جراحه الاورام جراحه الاورام ده يا عيني ما يفهمش يعني ايه اورام هو بيخش يشيل الورم هو مالوش دعوه بيه وبي بينقي الليمف نودز بينقي الغدد الليمفاويه الغدد الليمفاويه دلوقتي انت بتنقيها
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
肿瘤外科医生不懂肿瘤是什么：他们切除肿瘤并"清扫"淋巴结，他认为这是错误的。
出处
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr Diaa Al Awady د ضياء العوضي is live! السيليوليت (打开来源)
- 发布日期
- 2025年10月11日
- 时间戳
- 0:05:12 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Transcript is YouTube CC or machine-generated (no timestamps); wording may contain speech-recognition errors. Speaker attribution within live streams/podcasts is not marked in the transcript; the excerpt was judged to be Elawady's own speech from context. Recurrence = number of archive transcripts matching the keyword pattern ['الغدد الليمفاويه|الليمف', 'تشيل|بينقي|استئصال|يشيل'] (approximate; includes re-uploads/clips; 5 distinct text passages).
- 所声称的机制
Not stated in this excerpt.
- 所声称的健康影响
Not specified.
- 涉及人群
Cancer patients undergoing surgery.
- Elawady 设定的地域限制
none found; he does not limit this statement to a country or to a production system
来源版本存在差异
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr Diaa Al Awady د ضياء العوضي is live! لايف مفاجيء (打开来源)
- 发布日期
- 2025年8月5日
- 时间戳
- 无（转录文本不含时间信息）
- 归属的不确定性
- Further video in which the same statement recurs; no excerpt recorded. Archive transcript without timestamps.
科学评估
基本错误 – 该说法的主要部分没有证据支持，或被严重夸大。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么？
Surgical oncologists do not understand what tumours are; they remove the tumour and 'clean out' the lymph nodes, which he regards as wrong.
2. 哪些内容可证实是正确的？
Part of his criticism matches what oncology itself learned from trials: removing all axillary nodes did not improve survival compared with less extensive surgery over 25 years (I-INTB-05); in women with 1-2 positive sentinel nodes, skipping full axillary dissection was non-inferior for 10-year survival (86.3% vs 83.6%) (I-INTB-06); in melanoma, completion lymph-node dissection did not improve melanoma-specific survival and caused lymphoedema in 24.1% vs 6.3% (I-INTB-07). Arm lymphoedema affects about one in five breast-cancer survivors and is about four times more common after axillary dissection (I-INTB-08). The German INSEMA trial (5502 women) showed that in small, clinically node-negative breast cancers even sentinel-node biopsy can be omitted without worse 5-year disease-free survival (91.9% vs 91.7%), with less arm swelling (I-SRC-106).
3. 哪些内容是错误或夸大的？
The claim that surgical oncologists 'do not understand' tumours is a personal judgement, not a finding. The de-escalation of lymph-node surgery came from oncologists' own randomised trials. In all these trials the tumour itself was removed, and sentinel-node biopsy remained because nodal status gives prognostic information (I-INTB-07). Using alternative-only care instead of standard treatment for curable cancers was associated with higher death rates (I-CHM-03). In the US SEER registry, the 0.64% of breast-cancer patients who refused recommended surgery had about a 2.4-fold higher risk of death (observational; I-SRC-107). UK NICE guidance follows the trials: sentinel-node biopsy rather than full clearance, and further surgery when the tumour reaches the margin so that it is completely removed.
4. 哪些内容仍不明确？
How much lymph-node surgery is optimal differs by cancer type; this assessment used breast cancer and melanoma trials.
5. 哪些研究支持该说法？
6. 哪些研究与该说法相矛盾？
7. 对德国和欧洲而言情况如何？
European practice follows these trials (sentinel-node biopsy, less axillary dissection).
8. 关于埃及的已知情况是什么？
The same evidence applies; access to sentinel-node techniques may vary.
9. 合理的实际结论是什么？
对许多患者而言，减少淋巴结手术是恰当的，这由肿瘤治疗团队依据试验证据来决定。这并不是拒绝肿瘤手术的理由。
评估详情
- 证据确定性的依据
RCTs show that routine extensive lymph-node dissection does not improve survival in breast cancer and melanoma (I-INTB-05, I-INTB-06, I-INTB-07) and causes lymphoedema (I-INTB-08), which supports part of his criticism. The broader message - that surgical oncologists do not understand tumours and that removing tumours and nodes is wrong - is not supported; these trials all kept tumour removal and sentinel-node staging.
- 来源质量
Machine transcript of a live stream; wording may contain recognition errors; meaning checked in context.
- 地区可推广性
High; the same trial evidence underlies EU and Egyptian practice.
- 个体例外情况
The need for lymph-node surgery depends on tumour type, stage and node findings.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
过度解读 – 确有真实的发现，但该说法从中引申出的结论超出了数据所能支持的范围（例如把关联当作因果、把动物数据套用到人身上、把小效应说成大效应）。
研究问题: In solid cancers, does removing the tumour and (where indicated) staging or removing lymph nodes improve outcomes compared with less or no surgery?
研究问题详解 (PICO)
- 人群
- Patients with operable solid cancers (evidence mainly breast cancer and melanoma)
- 干预或暴露
- Tumour resection with lymph-node staging/dissection
- 对照
- Less extensive or no lymph-node surgery; no surgery
- 地域范围
- universal biology
- 结局指标
- Overall/disease-free survival
- Regional recurrence
- Lymphoedema
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Skipping armpit lymph-node surgery in small breast cancers
INSEMA RCT: omission of sentinel-node biopsy in cT1-2 cN0 breast cancer with breast-conserving surgery.
- 实际结果
- 5-y iDFS 91.9% vs 91.7%; HR 0.91 (0.73-1.14); less lymphoedema.
- 方法学质量
- high (large RCT)
- 相关性
- direct for less node surgery
- 局限
- Tumour removed in both arms.
Fewer lymph nodes removed, same survival
Z0011 RCT: no axillary dissection with 1-2 positive sentinel nodes.
- 实际结果
- 10-year survival 86.3% vs 83.6% (non-inferior).
- 方法学质量
- high
- 相关性
- direct for less node surgery
- 局限
- Selected patients.
Full lymph-node removal in melanoma did not extend life
MSLT-II RCT in melanoma.
- 实际结果
- Completion dissection did not improve melanoma-specific survival; lymphoedema 24.1% vs 6.3%.
- 方法学质量
- high
- 相关性
- direct
- 局限
- Sentinel biopsy retained.
哪些证据不支持该说法？
Refusing breast-cancer surgery
Gaitanidis A et al.. Clin Breast Cancer 2018 · PMID 28784267 · DOI 10.1016/j.clbc.2017.07.010 队列研究已核查摘要新增SEER: refusal of recommended breast-cancer surgery.
- 实际结果
- 0.64% refused; about 2.42-fold mortality risk.
- 方法学质量
- low (confounded)
- 相关性
- direct for refusing tumour surgery
- 局限
- No CI in abstract.
Patients who used only alternative medicine for curable cancer died more often
Alternative medicine instead of standard care.
- 实际结果
- Alternative medicine alone vs conventional treatment: death HR 2.50 (1.88-3.27); breast cancer HR 5.68 (3.22-10.04).
- 方法学质量
- low-moderate
- 相关性
- direct for replacing treatment
- 局限
- Observational; small alternative-medicine group.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Tumour removal remains essential; lymph-node surgery has been de-escalated by oncologists' own trials and is decided individually.
为什么有些研究权重更大
Large RCTs support less node surgery but all retained tumour removal; observational data on refusing surgery are confounded but consistent.
因果关系是否已确立？ 是，已确立 RCTs establish that less node surgery is safe in defined groups; tumour removal is part of every trial arm.
仍存在的不确定性
Optimal extent of node surgery differs by cancer type and stage.
合理的结论
He is partly right that routine extensive lymph-node removal is often unnecessary, but this insight comes from surgical oncology itself; the claim that surgeons do not understand tumours and that removing tumours is wrong is not supported.
为什么研究结果看起来互相矛盾？
这是否取决于国家？
- 一般生物学效应
- Universal.
- 饮食习惯
- Not applicable.
- 食品原产地
- Not applicable.
- 污染物
- Not applicable.
- 本国生产条件
- Not applicable.
- 法律规则
- NICE NG101 (UK) follows these trials.
- 实际监测数据
- Not applicable; access to sentinel-node techniques in Egypt may vary.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- HR CI symmetry and non-inferiority margin; absolute difference – HR 0.91 (0.73-1.14) symmetric; upper bound below 1.271; iDFS difference +0.2 points 已重新计算
- Proportion refusing; CI of mortality effect – 3389/531,700 = 0.64% (matches); mortality HR 2.42 given without CI - cannot be checked 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Survival after omitting tumour surgery
- 起始等级
- 低（观察性研究）
- 降级理由
- risk of bias: confounded observational data
- 升级理由
- large effect (about twofold mortality)
- 结果
- 低
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- NICE: NG101 Early and locally advanced breast cancer: diagnosis and management (last updated 14 April 2025) (2025) · 原始文献
Use sentinel-lymph-node biopsy rather than axillary clearance to stage the axilla when ultrasound/biopsy is negative; do not offer further axillary treatment for micrometastases or isolated tumour cells; offer further surgery when tumour is at the margin (0 mm) to ensure the tumour is fully removed. - ESMO: Early breast cancer: ESMO Clinical Practice Guideline (2024) · 原始文献 无法获取；内容未采用
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| PubMed | 2026年10月26日 | (omission OR omitting) sentinel lymph node biopsy breast cancer randomized trial (INSEMA OR SOUND) | 支持性证据 | 21 | |
| Europe PMC | 2026年10月26日 | (lymphadenectomy OR "lymph node dissection") AND (randomized OR randomised) AND (survival) AND (gastric OR colorectal OR melanoma OR breast OR endometrial) AND ("meta-analysis") AND PUB_YEAR:[2018 TO 2026] | 双向 | 4484 | |
| PubMed | 2026年10月26日 | (refusal OR refused OR declined) surgery breast cancer survival National Cancer Database | 反对性证据 | 62 | |
| PubMed | 2026年10月26日 | early breast cancer ESMO clinical practice guideline diagnosis treatment follow-up 2024 | 指南 | 3 | |
| NICE / ESMO / Annals of Oncology websites | 2026年10月26日 | NICE NG101 recommendations; ESMO early breast cancer guideline 2024 (ESMO page and Ann Oncol full text returned 403/no content) | 指南 | 3 |
核查深度如何？
7 项相关研究：2 项核查了全文（其中 2 项进行了结构化偏倚风险评估），5 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
通俗解释
Elawady 医生说，癌症外科医生不懂肿瘤，错误地"清扫"淋巴结。大型试验确实表明，切除许多淋巴结往往并不能提高生存率，还可能造成手臂或腿部的持久肿胀。由于这些试验，外科医生现在切除的淋巴结更少了。但同样的试验仍然切除了肿瘤，而检查少数几个"前哨"淋巴结仍然有用。拒绝癌症手术是危险的。
与该说法相关的研究
支持该说法的研究 (0)
该组中没有研究。
与该说法相矛盾或限制该说法的研究 (2)
-
Patients who used only alternative medicine for curable cancer died more often
Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145队列研究独立交叉核查已核查摘要★ 关键研究Risk of death was 2.5 times higher overall and 5.7 times higher for breast cancer.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare AM-only vs conventional treatment.
- 研究是如何开展的？
Matched registry cohort.
- 研究了多少人、动物或样本？
840 matched patients.
- 实际发现了什么？
HR 2.50 for death.
- 观察到的效应有多大？
HR 5.68 breast cancer.
- 研究结果对日常生活意味着什么？
Replacing cancer treatment with alternatives is dangerous.
- 该研究有哪些局限？
Observational.
- 它对 Elawady 的具体说法说明了什么？
Contradicts refusing therapy.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
Effects of complementary approaches used alongside treatment.
-
Refusing breast-cancer surgery
Gaitanidis A et al.. Clin Breast Cancer 2018 · PMID 28784267 · DOI 10.1016/j.clbc.2017.07.010队列研究独立交叉核查已核查摘要Patients who refused recommended surgery had a 2.4 times higher risk of death; the groups also differed in other ways.
Refusing recommended breast-cancer surgery associated with about 2.4-fold mortality (confounded).
该研究是否支持这一具体说法？ 否 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Study surgery refusal
- 研究是如何开展的？
Registry cohort
- 研究了多少人、动物或样本？
531,700 patients
- 实际发现了什么？
Refusal rare but linked to higher mortality
- 观察到的效应有多大？
2.42 times higher mortality risk
- 研究结果对日常生活意味着什么？
Refusing surgery is risky
- 该研究有哪些局限？
Observational, confounded
- 它对 Elawady 的具体说法说明了什么？
Contradicts distrust of tumour surgery
- 研究结果是否适用于德国和欧洲？
Direction applicable
- 从该研究中明确不能得出什么结论？
Exact causal effect
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (5)
-
Removing all armpit lymph nodes did not improve survival
Fisher B et al.. N Engl J Med 2002 · PMID 12192016 · DOI 10.1056/NEJMoa020128随机对照试验独立交叉核查已核查摘要★ 关键研究Over 25 years, women without routine axillary dissection survived as long as those with radical mastectomy.
Supports less lymph-node surgery; all arms removed the tumour.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare radical vs less extensive breast surgery
- 研究是如何开展的？
RCT
- 研究了多少人、动物或样本？
1665 women
- 实际发现了什么？
No survival difference
- 观察到的效应有多大？
HR 1.03-1.08, CIs include 1
- 研究结果对日常生活意味着什么？
Taking out more lymph nodes did not make women live longer; the breast tumour was still removed in all groups.
- 该研究有哪些局限？
Old trial; abstract only
- 它对 Elawady 的具体说法说明了什么？
Partly supports his criticism of lymph-node 'cleaning'; contradicts rejecting tumour removal.
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Cannot conclude that tumour surgery is unnecessary.
-
Fewer lymph nodes removed, same survival
Giuliano AE et al.. JAMA 2017 · PMID 28898379 · DOI 10.1001/jama.2017.11470随机对照试验独立交叉核查全文，含结构化偏倚风险评估★ 关键研究In women with 1-2 positive sentinel nodes, skipping full axillary dissection did not worsen 10-year survival.
Supports less lymph-node surgery, not abandoning tumour surgery.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test whether full lymph-node dissection is needed
- 研究是如何开展的？
RCT
- 研究了多少人、动物或样本？
891 women randomised (856 analysed)
- 实际发现了什么？
Survival non-inferior without dissection
- 观察到的效应有多大？
86.3% vs 83.6% at 10 years
- 研究结果对日常生活意味着什么？
Oncologists now remove fewer lymph nodes because trials showed it is safe in selected patients.
- 该研究有哪些局限？
Specific population; trial closed early with fewer patients and deaths than planned
- 它对 Elawady 的具体说法说明了什么？
Partly supports his point on lymph nodes; contradicts his claim that surgeons 'do not understand'.
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Cannot conclude that tumour removal, sentinel-node staging or lymph-node surgery in other situations (mastectomy, more positive nodes, palpable nodes) is unnecessary
-
Full lymph-node removal in melanoma did not extend life
Faries MB et al.. N Engl J Med 2017 · PMID 28591523 · DOI 10.1056/NEJMoa1613210随机对照试验独立交叉核查全文，含结构化偏倚风险评估Completion dissection did not improve melanoma-specific survival but caused more lymphoedema.
Supports less lymph-node surgery; nodal staging still valuable.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test completion lymph-node dissection
- 研究是如何开展的？
RCT
- 研究了多少人、动物或样本？
1939 randomised patients (1755 per protocol)
- 实际发现了什么？
No survival benefit; more lymphoedema
- 观察到的效应有多大？
86% vs 86% 3-year survival; lymphoedema 24.1% vs 6.3%
- 研究结果对日常生活意味着什么？
Removing more lymph nodes is not always better; doctors changed practice after this trial.
- 该研究有哪些局限？
Follow-up only about 3.5 years; per-protocol emphasis; requires regular ultrasound surveillance
- 它对 Elawady 的具体说法说明了什么？
Partly supports his criticism of lymph-node removal.
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Cannot conclude that sentinel-node biopsy or tumour removal is unnecessary; observation was safe only with intensive ultrasound follow-up
-
Arm swelling after breast-cancer lymph-node surgery
DiSipio T et al.. Lancet Oncol 2013 · PMID 23540561 · DOI 10.1016/S1470-2045(13)70076-7Meta分析独立交叉核查已核查摘要About 1 in 5 survivors develop arm lymphoedema; risk is about four times higher after full axillary dissection.
Supports harm of lymph-node removal.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Estimate lymphoedema incidence
- 研究是如何开展的？
Meta-analysis
- 研究了多少人、动物或样本？
72 studies
- 实际发现了什么？
16.6% overall; 19.9% after dissection vs 5.6% after sentinel biopsy
- 观察到的效应有多大？
about 4-fold
- 研究结果对日常生活意味着什么？
Removing many lymph nodes often causes lasting arm swelling.
- 该研究有哪些局限？
Heterogeneous studies; abstract only
- 它对 Elawady 的具体说法说明了什么？
Supports his concern about lymph-node removal as a harm.
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Cannot conclude that lymph-node surgery never benefits patients.
-
Skipping armpit lymph-node surgery in small breast cancers
Reimer T et al.. N Engl J Med 2025 · PMID 39665649 · DOI 10.1056/NEJMoa2412063随机对照试验独立交叉核查已核查摘要★ 关键研究Women with small breast cancers who had no lymph-node surgery did as well over 6 years as those who had a sentinel-node biopsy, with less arm swelling.
Supports reducing lymph-node surgery in selected patients; tumour removal was part of treatment in both arms.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test omitting lymph-node surgery
- 研究是如何开展的？
Randomised trial
- 研究了多少人、动物或样本？
5502 women
- 实际发现了什么？
No worse survival without node surgery; fewer arm problems
- 观察到的效应有多大？
5-y iDFS 91.9% vs 91.7%; HR 0.91
- 研究结果对日常生活意味着什么？
Less lymph-node surgery is often possible
- 该研究有哪些局限？
Mostly small tumours
- 它对 Elawady 的具体说法说明了什么？
Supports less node surgery but tumour was always removed
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Whether tumour surgery can be skipped (it cannot be concluded)
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
European practice follows these trials (sentinel-node biopsy, less axillary dissection).
埃及
The same evidence applies; access to sentinel-node techniques may vary.
在我的国家适用什么？
一般科学评估
基本错误 基于试验结果，常规的广泛淋巴结切除已经缩减，但切除肿瘤仍是癌症治疗的重要组成部分。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Use of Alternative Medicine for Cancer and Its Impact on Survival.. Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145
- Refusal of Cancer-Directed Surgery by Breast Cancer Patients: Risk Factors and Survival Outcomes.. Gaitanidis A et al.. Clin Breast Cancer 2018 · PMID 28784267 · DOI 10.1016/j.clbc.2017.07.010
- Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.. Fisher B et al.. N Engl J Med 2002 · PMID 12192016 · DOI 10.1056/NEJMoa020128
- Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.. Giuliano AE et al.. JAMA 2017 · PMID 28898379 · DOI 10.1001/jama.2017.11470
- Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.. Faries MB et al.. N Engl J Med 2017 · PMID 28591523 · DOI 10.1056/NEJMoa1613210
- Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis.. DiSipio T et al.. Lancet Oncol 2013 · PMID 23540561 · DOI 10.1016/S1470-2045(13)70076-7
- Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.. Reimer T et al.. N Engl J Med 2025 · PMID 39665649 · DOI 10.1056/NEJMoa2412063